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Abstract 
Background: Multiple sclerosis is characterised by white matter lesions, which are visualized with 
conventional T2-weighted MRI. Little is known about local metabolic processes preceding the 
appearance and during the pathological development of new lesions. 
Objective: To identify metabolite changes preceding white matter (WM) lesions and pathological 
severity of lesions over time. 
Methods: Fifty-nine relapsing-remitting MS patients were scanned four times, with six-month 
intervals. Imaging included short-TE MR spectroscopic imaging (MRSI)  and DTI.  
Results: Sixteen new lesions appeared within the MRSI slab in twelve patients. Glutamate increased 
(+1.0 mM (+19%), p=0.039) twelve to six months before new lesions appeared. In these areas, the 
increase of creatine and choline six months before until lesion appearance, were negatively 
correlated with  radial diffusivity (ρ=-0.73, p=0.002 and ρ=-0.72, p=0.002). Increase of creatine also 
correlated with increase of axial diffusivity in the same period ( ρ=-0.53, p=0.034 ). When splitting 
the lesions into 'mild' and 'severe' based on radial diffusivity, only mild lesions showed an increase in 
creatine and choline during lesion formation (p=0.039 and p=0.008 respectively).  
Conclusion: Increased glutamate heralded the appearance of new T2-visible WM lesions. In 
pathologically ‘mild’ lesions, an increase of creatine and choline was found during lesion formation.  
 
 
 
 Abbreviations 
0mp : zero month prior to appearance  
12mp : 12 months prior to appearance 
6mp : 6 months prior to appearance  
AD : axial diffusivity  
Cho : choline-containing compounds  
DTI : diffusion tensor imaging 
DTI-LM : DTI lesion mask  
EDSS : Expanded Disability Status Scale 
FWHM : full-width half-maximum 
Glu : glutamate 
GM: Grey matter 
Ins : myo-inositol 
mM: mmol/liter 
MRSI : Magnetic resonance spectroscopic imaging  
MRSI-LM : MRSI lesion mask 
MS: Multiple sclerosis 
NAWM: normal-appearing white matter 
RD : radial diffusivity  
SNR : signal to noise ratio  
tCr : total creatine  
tNAA : N-acetylaspartate and N-acetyl aspartylglutamate  
VOI : volume of interest 
WM: White matter 
 
 Introduction 
MS is an inflammatory, neurodegenerative disease that is characterized by focal WM lesions, 
amongst other pathological changes.1 Conventional T2-weighted MRI is an essential tool for 
diagnosis although the number of T2 WM lesions is a poor predictor of clinical disability.2 More 
advanced MRI techniques are needed to be able to detect varying degrees of (subtle) tissue damage 
within lesions or in the NAWM, to better explain clinical disability. MRS imaging (MRSI) and DTI 
are two such techniques, giving information about metabolism and tissue microstructure 
respectively.3-7 
 One previous study investigated metabolite changes prior to lesion appearance in MS8 and 
found an increased choline/creatine ratio in WM areas that later showed lesions. Metabolite changes 
during lesion formation have also been sparsely studied.9-13 A few studies reported increases of total 
creatine and choline or a transient decrease of total N-acetylaspartate or its ratio to creatine when 
following acute, gadolinium-enhancing lesions over time. The relation between metabolite changes 
and microstructural tissue damage over time has not been investigated before.  
In the present longitudinal study, we aimed to identify local metabolite changes both prior to 
and during WM lesion formation, using short echo-time MRSI. Changes in metabolite concentrations 
were related to changes in DTI-measured tissue damage in lesions, in order to study the predictive 
value of early metabolite changes in terms of lesion development and tissue damage. 
 
 Materials and methods 
Study design 
Fifty-nine relapsing remitting MS patients were included in this study and scanned four times, with a 
6 month interval. The study is exploratory and no a priori sample size was estimated. Data, part of 
the same group, have been published previously.14,15 Twenty-nine patients were starting natalizumab, 
nineteen patients were continuing interferon or glatiramer acetate and eleven patients were not using 
disease-modifying-drugs at the baseline measurement. Inclusion criteria were a diagnosis of 
clinically definite relapsing remitting MS,16 and an age between eighteen and sixty-five years. 
Patients with a history of neurological or psychiatric conditions (besides relapsing-remitting MS), or 
a history of alcohol or drug abuse were excluded. 
 
Standard Protocol Approvals, Registrations, and Patient Consents 
The research protocol was approved by the institutional ethics review board, and written informed 
consent was given by all subjects before participation. 
 
MRI Acquisition 
MRI was performed on a 1.5T whole-body scanner (Siemens Sonata, Erlangen, Germany) with an 
eight-channel receiver head coil. 
Metabolite spectra were measured with a 2D MRSI, point resolved spectroscopy (PRESS) sequence 
(TR/TE 3000/30 ms) on a 15mm thick slab, aligned to the pituitary-fastigium line, with the center 
touching the top of the corpus callosum (Fig.1A). Based on head size, the field-of-view was 160x160 
or 140x160 mm, and the corresponding volume of interest (VOI) was 80x100 or 70x100 mm. The 
use of 16x16 phase-encodings resulted in a voxel size of 1.5 or 1.3 ml. Reference 2D-MRSI datasets 
were acquired without water suppression using both head and body coils as receiver. The phase 
encoded acquired data were filtered with a hamming function to reduce the outside voxel volume 
contamination.  
 DTI was performed by a diffusion-weighted echo-planar acquisition (TR 8.500 ms, TE 86 ms and 
isotropic resolution, 2x2x2 mm) including 60 volumes with noncollinear diffusion gradients (b value 
of 700 s/mm2) and 10 volumes without directional weighting. 
Structural imaging included a 3D T1-weighted magnetization prepared rapid acquisition gradient-
echo (MPRAGE) (TR 2700ms, TE 5ms, TI 950ms, 176 sagittal slices, 1.3 mm section thickness, 
1.3x1.3 mm2 in-plane resolution), and a PD/T2-weighted turbo spin-echo (TR 3130 ms, TE 24 and 
85ms, 46 contiguous 3 mm axial slices, 1x1 mm2 in-plane, aligned to the 2D MRSI slab. No T1-
weighted contrast-enhanced imaging was performed. 
 
Lesion masks 
When a new lesion appeared in the MRSI slab during the study period, a lesion mask, i.e., a 3D 
volume delineating a region of interest, was manually created on the corresponding T2-
hyperintensity. New T2-Hyperintense MS lesions were assessed by experienced neuroradiologists 
and only diagnosed new lesions were retained for manual segmentation. The lesion mask was then 
registered onto the exact same areas of the preceding timepoints, using FLIRT.17 The WM 
surrounding the lesional area was also included, by dilating all lesion masks by 18mm. This reduced 
variability by including more MRSI voxels in the lesional masks. As a result, MRSI lesion masks 
(MRSI-LM) were createdat the appearance of the new T2 lesion (0mp), at 6 months prior to 
appearance (6mp) and at 12 months prior to appearance (12mp) (Fig.1C). WM lesions already visible 
at the first acquisition were dilated in plane by 2mm and included in a chronic lesion mask. Because 
this study focused on the metabolite changes preceding and during WM lesion formation metabolite 
concentrations in chronic lesion mask were dismissed and masked out. More details are given in the 
on-line supplementary material. 
 
Metabolite quantification  
 The spectrum of each MRSI voxel was quantified using LCModel20 resulting in absolute 
concentrations of N-acetylaspartate and N-acetyl aspartylglutamate (tNAA), total creatine (tCr), 
choline-containing compounds (Cho), myo-inositol (Ins) and glutamate (Glu) expressed in 
mmol/liter (mM). Glutamine levels were also quantified and checked in order to ensure a reliable 
Glu quantification (details given in on-line supplementary material). Quality assessment and 
reproducibility of the absolute metabolite quantification for these metabolites have been published 
previously.14 See on-line supplementary material for full details. 
 
Concentrations in lesion masks  
The 3D T1 images were lesion-filled using LEAP19 and segmented using SIENAX,17 producing grey 
matter (GM) and WM masks. Overlaps with MRSI-LMs were removed resulting in GM and NAWM 
masks. These were then divided in frontal and parietal lobe sub-masks based onthe ICBM 152 
nonlinear 2009c atlas (Fig.1B).20 More details about the steps are described in the on-line 
supplementary material. 
Using the collective of these masks, brain tissue within the MRSI slab was divided into MRSI-LMs 
at 0mp, 6mp and 12mp, chronic lesion mask, frontal grey or NAWM and parietal grey or NAWM. 
Metabolite concentrations were then estimated within each area by a extrapolation analysis. This 
post-processing method extrapolates concentrations within all the masks depending on their partial 
volume contributions to each MRSI voxel. Changes in metabolite concentrations in MRSI-LM were 
calculated for every 6 months period between two acquisitions (Fig.1C): the prelesional period 
(differences between 12mp and 6mp in MRSI-LM) and the lesion formation period (differences 
between 6mp and 0mp in MRSI-LM). Additional details are given in the on-line supplementary 
material. 
 
 DTI within lesions 
Diffusion tensor images were fitted to a tensor model resulting in 3D volumes of axial diffusivity 
(AD) and radial diffusivity (RD) in 10-5 mm2/s, using DTIFIT.17 DTI lesion masks (DTI-LM) were 
delineated identically to the MRSI-LMs (Fig.1C) but not dilated (due to the higher spatial resolution 
and SNR of the DTI measurements). The mean values for AD and RD were then calculated inside 
DTI-LM at 12mp, 6mp and 0mp. The DTI metric changes in DTI-LM between the different 
timepoints were then calculated in the same way as for the metabolite concentrations leading to ΔAD 
and ΔRD during the prelesional period (differences between 12mp and 6mp) and the lesion 
formation period (differences between 6mp and 0mp). AD and RD are known to increase markedly 
with the formation of a new WM lesion21 and the level of RD found in new, enhancing lesions is 
thought to reflect the severity of the tissue damage.22,23 Hence, the amount of ΔRD during the lesion 
formation period was considered as a degree of lesion severity. 
 
DTI changes over time and the classification of lesions as ‘mild’ or ‘severe’  
To explore the change in DTI metrics occurring in the lesions, the significance of the changes of 
ΔAD and ΔRD was assessed during the prelesion and lesion formation periods. To identify possible 
metabolite markers specific to a lesion severity subtype, two subgroups of lesions were created. The 
lesions above the median ΔRD were defined as ‘severe’ and the lesions below the median as ‘mild’.  
 
Metabolite concentration changes during the prelesional period  
To investigate whether and which metabolic changes occur before the appearance of new WM 
lesions, we measured the changes in concentrations during the prelesional period in the MRSI-LMs. 
If a metabolite showed a pre-lesional change, the same test was performed, as surrogate analysis, on 
the corresponding changes in concentration ratio with respect to tCr and additionally with MRSI-LM 
 at 12mp and 6mp mirrored in the contralateral hemisphere. Finally, the concentration changes in 
NAWM were also analyzed to check their stability.  
As a posteriori analysis, the correlation was calculated between the significant changes in metabolite 
concentrations in the prelesional period and the changes in DTI metrics during the lesion formation 
period and the volume of the newly formed lesions.  
 
Metabolite concentration changes during the lesion formation period and relations with 
lesion severity  
The significance of the metabolite concentrations changes during the lesion formation period was 
determined either in all the lesions combined or in the 'mild' and 'severe' subgroups. 
In an a posteriori analysis, the correlation between metabolite concentrations exhibiting significant 
changes and ΔAD and ΔRD during the same time period were assessed. Correlation coefficients 
were also computed between concentration changes during the lesion formation period and the 
volume of the newly formed lesions. 
 
Statistical analysis 
Statistical longitudinal assessments of metabolite concentrations were performed using a Wilcoxon 
signed-rank test between the applicable timepoints. The DTI metrics change were statistically 
analyzed with a Student's t-test on paired data of the applicable timepoints. Correlations coefficients 
were computed using the Spearman’s rank correlation.The tests were considered significant when the 
probability value, p, was less than 0.05 (values are given as mean ± standard deviation, unless 
indicated otherwise). Due to the exploratory nature of the study no adjustment for multiple 
comparisons was made. 
 
 Results  
Subjects 
Twelve patients showed one or more formations of new lesions within the MRSI slab. These patients 
had a mean age of 37 years (range 20-50) and mean disease duration of 4.6 years (range 0.16-13.3) at 
first acquisition. Only data of these subjects were retained for further analysis.  
Five patients received interferon beta-1b or glatiramer acetate whereas seven patients were untreated. 
Mean (standard deviation) normalized brain volume, normalized WM volume and normalized GM  
volume17 were respectively 1.39 L (±0.07 L), 0.68 L (±0.04 L) and 0.72 L (±0.04 L). The median T2 
lesion load was 4.3 mL (interquartile range: 2.1-11.9 mL). Median Expanded Disability Status Scale 
(EDSS) was 2.0 (range 1-3.5). Spectral qualities of the VOI in the MRSI slab were comparable to a 
previous reproducibility study,14 with a mean full-width at half-maximum (FWHM) of 5.18 Hz 
(±0.81 Hz) and a mean signal-to-noise ratio (SNR) of 10.8 (±1.35). 
In total, sixteen newly forming WM lesions were monitored over time. Data in the prelesional period 
were only available for nine lesions (seven lesion appeared at the second acquisitions) and lesion 
formation period data were available for the entire sixteen lesions. AD and RD did not change during 
the pre-lesional period but increased during the lesion formation period (Table 1). 
 
Pre-lesional period: glutamate increase 
An increase of +19% on average (p=0.039) was measured for Glu during the pre-lesional period ( 
ΔGlu = 1.0 ±1.3 mM) (Fig.2A, Table 1). Other metabolites remained stable within the pre-lesional 
period and Glu in the contralateral (control) region also showed no changes. Analysis of the change 
of concentration ratio Δ(Glu/tCr) confirmed the pre-lesional increase, on average of +23% (p=0.027, 
Δ(Glu/tCr)=0.26 ±0.31 ). The metabolite concentrations in NAWM did not show any significant 
changes in both the pre-lesion and the lesion formation period (Table e-1). 
 In the posthoc analysis, pre-lesional ΔGlu was associated with ΔAD of the lesion formation period (ρ 
= 0.86; p<0.003) (Fig.2B); pre-lesional ΔGlu was also associated with the volume of the new lesion 
(ρ=0.68; p=0.050) (Fig.2C) but not with ΔRD of the lesion formation period (Table 2).  
 
Lesion formation period: Increase of tCr and Cho in developing 'mild' lesions 
During the lesion formation period, only the subgroup of 'mild' lesions showed increases in 
metabolite concentrations: tCr was found to increase by 23% (p=0.039, ΔtCr = 0.89 ±0.86 mM) and 
Cho by 27% (p=0.008, ΔCho = 0.35 ±0.24 mM ) (Table 1). 
In the a posteriori analysis, the values of ΔtCr and ΔCho in all lesions during the lesion formation 
period were strongly associated with ΔAD and ΔRD in the same period. ΔtCr was anti-correlated to 
ΔRD (ρ -0.73, p = 0.002) and ΔAD (ρ -0.53, p = 0.034). ΔCho was anti-correlated with ΔRD (ρ -
0.72, p = 0.002) (Fig.3C-D). ΔtCr and ΔCho were not correlated to the lesion volume (Table 2). 
 
 Discussion 
This study investigated and related metabolite and diffusion changes prior to and during new WM 
lesion formation in MS. Glutamate increases were found to precede the development of new WM 
lesions on T2-weighted MRI scans. Furthermore, tCr and Cho increases were associated with lower 
increases of RD and AD in the developing lesions. And finally, pre-lesional Glu increase was 
indicative of higher subsequent lesion volumes and AD increases. 
 
Pre-lesional period 
Although a higher level of glutamate in NAWM and in acute WM lesions has been previously 
reported,24,7 the observation of Glu rising prior to WM lesion appearance is new and important. The 
rise in Glu could be attributed to activated macrophages and/or microglia, which are known to cluster 
in the pre-lesional stages25,26 and to produce Glu.27 Other explanations might be subtle pathology of 
axons or abnormalities of Glu receptor/transporter biology leading to abnormal parenchymal Glu 
concentrations.28  
The Glu increase during the pre-lesional period was strongly correlated with the AD increase, which 
is generally deemed to relate to axonal injury.4,5,29-31 The early pathological changes discussed above 
may therefore be indicative of the extent of eventual axonal damage within newly developing WM 
lesions in MS. Moreover, a stronger increase of Glu in pre-lesional WM was also associated with 
higher subsequent lesion volumes. Although there is an obvious effect of the lesion volume on the 
metabolite estimated within MRSI-LMs (considering the dilation of the lesion mask, the amount of 
actual T2-hyperintense tissue in MRSI-LM would be greater for larger lesions than for smaller 
lesions), the correlation in Fig.2c is particularly important because the Glu changes were measured 6 
months before the T2-hyperintensity appeared and before the actual lesion volume could be 
observed. This correlation suggests that changes of Glu in WM including and surrounding the future 
lesions could also predict their volume. Together, these results underline the relevance of Glu to 
predict both the extent and severity of the subsequently forming lesions.  
 The relevance of increased WM Glu as biomarker of MS progression and clinical disability has been 
already demonstrated in one recent clinical study7 where the ratio Glu/tNAA was associated with 
decline of brain volume and higher clinical disability.  
No changes in tCr or Cho were found in the pre-lesional period, in constrast with Tartaglia et al. .8 
This discrepancy could be explained by a difference in methodology. We investigated longitudinal 
absolute metabolite concentration changes, whereas Tartaglia et al. followed a cross-sectional 
approach. Additionally, the metabolite mask-matching analysis used in this study is beneficial for 
the precision of the results as the method corrects for intertwining of several tissue types (NAWM, 
GM, cerebrospinal fluid and lesional WM), and anatomical regions, known to differ natturally in 
terms of metabolite concentrations.32  
 
Lesion formation period 
In the lesion formation period, the lesions showing a high increase in tCre exhibited a small increase 
in AD and RD and vice versa. Likewise, when a high increase of Cho was observed, the increase in 
RD remained small. In fact, splitting the lesions into two groups ('mild' and 'severe') based on the RD 
increase, demonstrated that the effect is driven by the 'mild' lesions: increases of tCr and Cho were 
only present in the 'mild' lesion group. The increase of RD, which might reflect demyelination,33 is a 
strong predictor for evolution of the new lesion into a black hole (a sign of permanent and severe 
tissue damage).22,23 The metabolite variation in time and strong heterogeneity between lesions has 
already been described in magnetic resonance spectroscopy studies of acute WM lesions9-12 but the 
origin of this variability remained unclear.  
The observed increases of tCr and Cho could potentially be interpreted as a sign of remyelination, 
limiting  damage in new lesions. This role for tCr was suggested before by a study that followed new 
contrast-enhancing lesions over time. These lesions showed increases of tCr, which was interpreted 
as a reflection of repopulation of the lesions with oligodendrocytes and, hence, remyelination.13 
 
 Our findings suggest that early metabolite changes predict the appearance and also the severity of 
newly forming lesions. Monitoring these changes could be useful for choice and timing of 
pharmacotherapeutical interventions, but also for understanding disease heterogeneity and clinical 
progression. Especially as the increasing Glu before lesion appearance could also be interpreted as an 
early leakage of the blood brain barrier causing inflammatory infiltrates stimulating clustering of 
activated glial cells.  
 
Methodological considerations and future directions 
Larger sample sizes, perhaps with multiple MRSI slabs, applied and measured, may be needed to 
support our results further. Furthermore, the actual time of lesion formation could not be determined 
more precisely in this study than with the six month window of the lesion formation period. 
However, this should not affect the validity of our results. Indeed, DTI metrics changes recorded in 
the WM lesions of MS patients were reported to appear during the first month23 or two months34 
after enhancement, which falls entirely within the 6 months of the formation period taken into 
account here. Only the few lesions occurring in the last month of the formation period could have a 
possible incomplete increase of AD and RD that might have slightly reduced the overall effect. 
It is important to mention that DTI metrics changes and metabolite changes are measured on 
different mask sizes and that the lesion volume could affect the results in certain cases. Indeed, due 
to the dilation, the actual relative content of T2-hyperintense tissue in MRSI-LMs of small lesions is 
considerably lower than for larger lesions. Therefore, it is important to consider this effect when 
interpreting correlation between metabolite changes in MRSI-LM and DTI metrics changes.  
Imaging more frequently between time points and including contrast-enhancement could provide a 
more accurate characterization of metabolite changes as these are known to fluctuate in the month 
following the lesion formation.12,13 Including a T1-weighted spin-echo sequence would enable the 
correlation of our findings to chronic T1-hypointensities, as a clinically used measure of (severe 
and/or lasting) tissue destruction.35 Future studies are also required to observe whether a decrease of 
 tNAA follows eventually at longer follow-up, and how this would be related to our findings. 
 
Conclusions 
Our results show that a Glu increase precedes the appearance and predicts the volume of the new T2 
lesions in the MS WM, and that tCr and Cho increases predict the severity of tissue damage within 
those lesions. These findings are of essence for understanding lesion development in MS, and for 
therapeutic strategies or disease prediction.  
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